Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SEPN
SEPTERNA INC
NASDAQ
$38.91
▼ DOWN 3.85% (-1.56)

KEY STATISTICS

Market Cap$1.75 B
52w High$51.10
52w Low$11.98
Dividend Yield—
Frequency—
P/E-36.03
Volume385.85K
Shares Out.45.08M

COMPANY

LEADERSHIP

Jeffrey T. Finer
CHIEF EXECUTIVE
Jeffrey T. Finer

COMPENSATION 2026

Salary$635,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$5,000
Total$2,933,339

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 25, 2024
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
123

PRICE TARGET

Target High$60.00
Target Low$43.00
Target Median$50.00
Target Consensus$52.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$20.78M
NOV
9
MON

PRICE

$38.91 ▼ DOWN 3.85% (−$1.56)
$39.00$39.75$40.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM38.91

About Septerna Inc

https://septerna.com ↗

Septerna, Inc. is a South San Francisco-based biotech company developing oral small molecule GPCR-targeted therapies for endocrinology, immunology, inflammation, and metabolic diseases.

INDUSTRY

Biotechnology

A PRODUCT SEPTERNA INC IS KNOWN FOR

SEP-631
SEP-631

Septerna's promising oral small molecule drug candidate for chronic spontaneous urticaria and mast cell diseases is in Phase 1 trials, with upcoming data presentation making it their most notable potential product.

COMPETITORS

COMPETITOR
CLDX COMPARE
GPCR COMPARE
NVS COMPARE
TECX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
119
LISTED HERE
24
RANKED BY POSITION SIZE
VTI
0.00% · 927.7K
XSU.TO
0.03% · 571.0K
XPH
1.11% · 161.6K
SCHA
0.02% · 110.6K
AVSC
0.08% · 59.1K
DFAS
0.01% · 24.3K
XRS2.F
0.03% · 20.2K
JPSE
0.13% · 19.0K
ONEQ
0.01% · 17.5K
FSCC
0.18% · 14.2K
GSSC
0.04% · 10.6K
RSSL
0.03% · 10.5K
PRFZ
0.01% · 8.8K
BBC
0.67% · 8.7K
MMSC
0.59% · 7.8K
PILL
0.75% · 4.6K
SQLV
0.21% · 2.1K
RTWP.L
0.04% · 2.1K
ACSG
0.16% · 2.1K
SYZ
0.10% · 1.7K
BIB
0.06% · 1.6K
WSGE
0.03% · 474
RESM
0.05% · 79
USUE.DE
0.00% · 62

INSTITUTIONAL OWNERSHIP

SHARES OWNED
90.38%
HOLDERS
181
TOP 12 OF 181 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
7.0M sh · $234.29M
Trv Gp V, LLC
6.2M sh · $208.16M
Driehaus Capital Management LLC
4.9M sh · $92.54M
Trv Gp Vi, LLC
4.2M sh · $141.05M
Bvf Inc/Il
4.0M sh · $75.54M
Samsara Biocapital, LLC
3.1M sh · $59.24M
Goldman Sachs Group Inc
3.1M sh · $102.57M
Siren, L.L.C.
2.2M sh · $41.43M
Blackrock, Inc.
1.9M sh · $64.71M
Vanguard Group Inc
1.5M sh · $28.57M
Avoro Capital Advisors LLC
1.3M sh · $25.16M
Adar1 Capital Management, LLC
1.2M sh · $22.13M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
10 PERCENT OWNER
Third Rock Ventures V, L.P.
Sale · 147.1K shares
2026-08-12
★
10 PERCENT OWNER
Third Rock Ventures V, L.P.
Sale · 141 shares
2026-08-12
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Sale · 746.5K shares
2026-08-12
★
OFFICER: PRESIDENT AND COO
Bhatt Elizabeth
Purchase · 18.7K shares
2026-08-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 3
STRONG BUY 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Jones Trading BUY Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY Guggenheim BUY Truist Securities BUY Raymond James STRONG BUY Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
FTRE$18.81COMPARE
BCAX$23.43COMPARE
KURA$12.66COMPARE
MRVI$7.68COMPARE
ABUS$5.07COMPARE
PRME$3.61COMPARE